



WO 01/00262 A1



**Published:**

— With international search report.

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

- 1 -

Inhalers

5 The present invention relates to inhalers and in particular inhalers for the delivery of a medicament to the lung, more particularly a medicament in powder form.

In recent times, there has been a growing interest in the systemic delivery of pharmaceutically-active medicaments via the lung. Such a method of delivery is  
10 generally more attractive to the patient than methods such as injection, because it does not involve a needle and can be carried out discreetly in public.

In the case of medicaments in liquid form, the provision of an inhalable aerosol of the medicament can  
15 be achieved with a nebuliser or the like. A known device for generating a turbulent airflow in a nebuliser is a so-called "cyclone". The cyclone comprises a cylindrical chamber with an axial outlet and a tangential inlet.

20 However, for a medicament in solid form, such as crystals, the provision of an inhalable aerosol is more difficult, because it is necessary to achieve a large repeatable dose of fine particles. In order for the particles of medicament to reach the lung and thus be  
25 absorbed into the bloodstream, the particles must have an effective diameter approximately in the range 3-5  $\mu\text{m}$ . If the particles are larger than 5  $\mu\text{m}$  they may not be transported by the inhaled airflow deep into the lung, because they are likely to be trapped in the respiratory  
30 passages before reaching the deep lung. For example, particles of the order of 10  $\mu\text{m}$  are unlikely to progress further than the trachea and particles of the order of 50  $\mu\text{m}$  tend to deposit on the back of the throat when inhaled. Furthermore, if the particles are less than 1  
35  $\mu\text{m}$  in effective diameter, the particles may not be absorbed in the lung, because they are small enough to be expelled from the lung with the exhaled airflow.

- 2 -

Thus, it will be seen that it is important that the powdered medicament is delivered with an accurately controlled range of particle size in order that it is absorbed effectively in the lung.

5       It is known for the powdered medicament to be mixed with an excipient (an inert substance, such as lactose, which is combined with the medicament to prepare a convenient dosage form) of relatively large particle size, for example 50-100  $\mu\text{m}$ , to improve the handling  
10       properties of the medicament. The medicament attaches electrostatically to the surface of the excipient. In some cases, the particles of medicament agglomerate to form particles of a larger effective diameter. In  
15       either case, it is necessary to separate the medicament particles from the excipient and from each other in order to provide an inhalable aerosol which will deliver the medicament for absorption through the lung.

      In order to separate the particles, shear forces must be generated between the particles, for example by  
20       providing a substantial velocity gradient across the particles. This may be done, for example, by forcing the powder through a narrow nozzle at high speed or introducing the powder into a turbulent air stream.

      In traditional metered dose inhalers (MDIs) it is  
25       common for the emitted dose (the amount of medicament that enters the patient's airway) to be around 80-90% of the dose ejected from the inhaler. The respirable dose (the amount of medicament that reaches the lung) may be only around 50% of the emitted dose. However, the  
30       variation in the respirable dose of known inhalers can be  $\pm 20$ -30%. Such variation may be acceptable in the case of asthma drugs and the like, but when the medicament is a more potent drug such as insulin, growth hormone or morphine, this amount of variability in the  
35       dosing is unacceptable. The relatively low respirable dose also represents a significant wastage of what may be an expensive drug. Furthermore, there may be side

- 3 -

effects if the proportion of the emitted dose which is not respired is swallowed.

Thus, it is important for the systemic delivery of medicaments by inhalation that a repeatable dose of fine  
5 particles can be produced.

It is known for so-called "spacers" to be used in the generation of the aerosol from a metered dose inhaler. The spacer fits onto the mouthpiece of the inhaler and comprises a chamber into which the dose of  
10 medicament is ejected by the inhaler. The patient is then able to inhale the dose from the spacer through a corresponding mouthpiece on the spacer.

Large volume spacers are used where the patient is unable to inhale at the same time as operating the  
15 metered dose inhaler due to a lack of coordination. Small volume spacers are used to trap large particles which would stick to the back of the throat and may cause undesirable side-effects.

The present invention, at least in its preferred  
20 embodiments, seeks to provide an inhaler for generating an inhalable aerosol of a powdered medicament with an effective particle size that is sufficiently small for the medicament to be delivered to and absorbed in the lungs of a patient.

25 Thus, viewed from a first aspect the invention provides an inhaler comprising:

a chamber having a mouthpiece;

a cyclone arranged to eject an aerosol of  
medicament into the chamber; and

30 a drug dosing device arranged to provide a dose of powdered medicament entrained in an airflow to the cyclone.

In use of the inhaler, the powdered medicament is entrained in an airflow by the drug dosing device and  
35 expelled through the cyclone into the chamber as an aerosol for subsequent inhalation by a patient.

Thus, the invention provides a simple arrangement

- 4 -

which can generate an inhalable, fine-particle dose of a dry powder medicament.

In general, the cyclone is configured as a substantially cylindrical cavity provided with a tangential inlet and an axial outlet. The cyclone may be provided with a frustoconical portion in the region of the outlet for directing the airflow within the cyclone towards the outlet.

In one arrangement, the cyclone is provided with a further axial inlet. The further axial inlet is arranged to introduce the medicament close to the axis of the cyclone to reduce deposition of the medicament on the internal surfaces of the cyclone.

It is desirable for the cyclone to generate as much shear as possible within the airflow. At small radii, close to the axis of the cyclone, the high angular velocities increase the effective viscosity of the air causing a central cylindrical region lying along the axis to rotate as a rigid body within which the shear forces are minimal. Thus, according to an advantageous arrangement, the cyclone is provided with an axial member for directing the medicament towards the walls of the cyclone. In this way, the aerosol is unable to enter the very central zone of the cyclone where the shear forces are at a minimum. Alternatively or in addition, the outlet of the cyclone may be annular to encourage the airflow away from the central axial region of the cyclone.

It is also desirable to reduce the amount of deposition in the chamber of the inhaler and to allow a smaller chamber to be used. Thus, a diffuser may be provided at the outlet of the cyclone. The diffuser may comprise an axial and/or an annular diffuser with a gradual increase in cross-sectional area, preferably with an exponential increase in area for improved diffusion.

A small chamber may be provided at the outlet of

- 5 -

the cyclone comparable in volume to the cyclone itself to act as a diffuser. Similarly, a spacer may be provided at the outlet of the cyclone to act as a diffuser.

5           A plurality of cyclones may be provided such that their outlet flows coincide and interfere with each other to create extra shear forces.

          The airflow to the drug dosing device may be provided by an external air source, for example a source  
10 of compressed air. In a preferred arrangement, however, the airflow is provided by a pump in the inhaler. Thus, the inhaler may comprise a pump. The pump may be in the form of, for example, a piston pump, a resilient bladder or a source of compressed gas, such as a gas canister.  
15 Preferably, the pump is arranged to provide an airflow of repeatable volume and velocity. Thus, the pump may take the form of a spring-powered piston received in a cylinder.

          It has been identified that a problem associated  
20 with inhalers of the type according to the invention is that when the aerosol is expelled into the chamber, the aerosol tends to interact unfavourably with the air in the chamber. It is known for the chamber to be open and for the air initially within the chamber to be expelled  
25 through the mouthpiece of the chamber as the aerosol is introduced through a nozzle. However, this has been found to be unsatisfactory as the amount of medicament which escapes through the mouthpiece before the user inhales is unquantifiable.

30           Thus, viewed from a further aspect, the invention provides an inhaler comprising:

          a chamber having a mouthpiece; and

          an aerosolising device having an inlet for taking  
in an airflow and an outlet for expelling an aerosol  
35 into the chamber, wherein the inlet of the aerosolising device is connected to the chamber, such that, in use, the airflow is drawn from the chamber to generate the

- 6 -

aerosol.

Thus, according to this aspect of the invention air from within the chamber passes through the aerosolising device to generate the aerosol so that the chamber can  
5 be filled with aerosol without expelling air, and potentially medicament, through the mouthpiece of the chamber.

The aerosolising device may comprise a cyclone and/or a drug dosing device as previously described. The  
10 aerosolising device may also comprise a pump arranged to draw air from the chamber via the inlet.

In one arrangement, the chamber receives a plunger which is arranged to force air through the aerosolising device as the plunger moves through the chamber. In a  
15 particularly preferred embodiment, the aerosolising device is mounted on the plunger.

Thus viewed from a yet further aspect the invention provides an inhaler comprising a chamber having a mouthpiece and a plunger received in the chamber,  
20 wherein the plunger is arranged to force air through an aerosolising device to generate an aerosol of medicament in the chamber for inhalation through the mouthpiece.

Some embodiments of the invention will now be described by way of example only and with reference to  
25 the accompanying drawings, in which:

Figure 1 shows a cyclone for use in the invention;

Figure 2 shows a first embodiment of the invention;

Figure 3 shows a second embodiment of the invention;

30 Figure 4 shows a third embodiment of the invention;

Figure 5 shows a fourth embodiment of the invention; and

Figure 6 shows a fifth embodiment of the invention.

Corresponding reference numerals have been used for  
35 corresponding parts in each embodiment of the invention.

Figure 1 shows a cyclone 1 for use in aerosolising a powdered medicament according to the invention. The



- 7 -

cyclone 1 is in the form of a cylinder 3 of a diameter between about 2 and 15 mm, preferably between 4 and 10 mm. The cylinder 3 is closed at an input end and provided with a frustoconical portion 5 at an output end. The cyclone 1 has an inlet 9 in the region of the closed input end of the cylinder 3, which input 9 is substantially tangential to the wall of the cylinder 3. The frustoconical portion 5 has an outlet 7 defined therein, which outlet 7 is concentric with the axis of the cylinder 3.

In use, an airflow entrains a powdered medicament and enters the cyclone 1 through the tangential inlet 9, as indicated by arrows A. The airflow (and medicament) is directed by the internal surface of the cylinder 3 in a helical path towards the outlet 7. The frustoconical portion 5 of the cyclone 1 narrows the radius of the helical path, thereby increasing the speed of the airflow and increasing the shear forces on the entrained medicament. Consequently, an aerosol of powdered medicament having particles of respirable size issues from the outlet 7 of the cyclone 1, as indicated by arrows B.

Figure 2 shows a first embodiment of the invention. According to this embodiment a cyclone 1 is connected to a chamber 11 having a mouthpiece 13. The chamber has a volume of around 300 ml. The cyclone 1 is located at an end of the chamber 11 opposite the mouthpiece 13, and the outlet 7 of the cyclone 1 is arranged to eject the aerosol of medicament into the chamber 11 towards the mouthpiece 13, as indicated by arrows B.

A drug dosing device 15 is connected to the inlet 9 of the cyclone 1 and is arranged such that, as a flow of air passes through the dosing device 15, a controlled dose of medicament is entrained in the airflow.

The airflow to the drug dosing device 15 is provided by a pump 17, which comprises a plunger 19 received in a pump cylinder 21 and biased towards an

- 8 -

outlet 23 of the pump 17 by a spring 25. A breath-actuated mechanism (not shown) is used to retain the plunger 19 in a retracted position against the biasing force of the spring 25 until the medicament is to be delivered.

In use, this embodiment of the invention operates as follows. The user primes the inhaler by pulling the plunger 19 of the pump 17 into the retracted position where it is retained by the breath-actuated mechanism. The user then inhales through the mouthpiece 13 of the chamber 11 and the resultant drop in pressure causes the breath-actuated mechanism to release the plunger 19 which forces a jet of air through the outlet 23 and the drug dosing device 15. The flow of air entrains a measured dose of medicament from the dosing device 15 and carries this dose into the cyclone 1. In the cyclone 1, the dose of medicament is aerosolised, as described in relation to Figure 1, and is expelled into the chamber 11 through the outlet 7, as indicated by the arrows B. The user is then able to inhale the aerosol of medicament into the deep lung via the mouthpiece 13.

Figure 3 shows a second embodiment of the invention. In this embodiment, the arrangement of the pump 17, dosing device 15 and cyclone 1 corresponds substantially to that of the embodiment of Figure 2. However, in this case the chamber 11 is larger than that shown in Figure 2 and the mouthpiece 13 is offset from the axis of the chamber 11 and of the cyclone 1. The mouthpiece 13 is provided with a cap 27 which closes off the mouthpiece, sealing the chamber 11 from the atmosphere. The cap 27 also closes off an air intake passage 29 which is provided in the chamber 11 to allow air to enter the chamber 11 when the user inhales through the mouthpiece 13. The chamber 11 connects to the outlet 23 of the pump 17 via an air passage 31 and a first non-return valve 33. A second non-return valve 35 is provided between the outlet 23 of the pump 17 and the

- 9 -

drug dosing device 15.

In operation of this embodiment, the plunger 19 of the pump 17 is withdrawn (as in the embodiment of Figure 2) which causes air to be drawn out of the chamber 11 through the air passage 31 and into the pump cylinder 21 via the first non-return valve 33. In this manner, the pressure in the chamber 11 is reduced to below atmospheric. It is to be noted that the release of the plunger 19 in this embodiment is not effected by a breath-actuated device but by a manually actuated release mechanism (not shown). When the release mechanism is actuated, the plunger 19 forces a jet of air through the second non-return valve 35 into the drug dosing device 15 where a measured dose of the medicament is entrained in the air stream. The airflow and entrained medicament pass into the cyclone 1 where the medicament is aerosolised and expelled from the outlet 7 of the cyclone 1 into the chamber 11, as indicated by the arrows B. The reduced pressure in the chamber 11 at this point ensures an even distribution of the aerosol within the chamber 11. The pressure is equalised by the ejection of the aerosol into the chamber 11. Once the aerosol has been delivered into the chamber 11, the user removes the cap 27 and inhales the aerosol through the mouthpiece 13.

Figure 4 shows a third embodiment of the invention. According to this embodiment, there is no pump 17, but a plunger 19 is provided within the chamber 11 so that the chamber itself acts as a pump cylinder. Thus, as the plunger 19 is driven in the direction of the arrow C, air is forced out of the chamber 11 through the air passage 31 and into the drug dosing device 15. As the air passes through the drug dosing device 15 it entrains a measured dose of medicament which passes into the cyclone 1 and is aerosolised and expelled into the chamber 11, as indicated by the arrows B. The user inhales the aerosol of medicament by removing the cap 27

- 10 -

and inhaling through the mouthpiece 13.

Figure 5 shows a fourth embodiment of the invention according to which the cyclone 1, the drug dosing device 15 and the air passage 31 are mounted on the plunger 19 and are movable therewith such that when the plunger 19 is moved in the direction of the arrow C, air from the lower half of the chamber 11 passes into the air passage 31 and through the drug dosing device 15, so that an aerosol of medicament is expelled from the cyclone 1 into the upper half of the chamber 11, in the direction of the arrows B.

Figure 6 shows a fifth embodiment of the invention which corresponds substantially to that of Figure 4 except that the cyclone 1 in this embodiment is located in a lower region of the chamber 11 and the direction of movement of the plunger 19 to generate the aerosol is reversed, as indicated by arrow C.

The embodiments of Figures 3 to 6 each have the particular advantage that the airflow which is used to entrain the medicament and generate the aerosol via the cyclone 1 is drawn from the chamber 11. Thus, a substantially equal volume of air is withdrawn from the chamber 11 to generate the aerosol as is returned to the chamber 11 when the aerosol is expelled from the cyclone 1. In this way, there is no requirement for the chamber 11 to be vented to atmosphere while the aerosol is generated and there is therefore no risk that any of the medicament will be lost before inhalation by the user.

Although there have been described herein a number of discrete embodiments, the features described in relation to any particular embodiment may be used in combination with the features of other embodiments described herein.

Although the aerosol of medicament has been described herein as an aerosol of powdered medicament in air, the medicament may be dispersed in any other gas or mixture of gases, as required.

- 11 -

Claims

1. An inhaler comprising:  
a chamber having a mouthpiece;  
5 a cyclone arranged to eject an aerosol of  
medicament into the chamber; and  
a drug dosing device arranged to provide a dose of  
powdered medicament to the cyclone.
- 10 2. An inhaler as claimed in claim 1, wherein the drug  
dosing device is arranged to provide a dose of powdered  
medicament entrained in an airflow to the cyclone.
- 15 3. An inhaler as claimed in claim 1 or 2, wherein the  
cyclone is in the form of a cylinder of a diameter  
between about 2 and 15 mm.
- 20 4. An inhaler as claimed in claim 3, wherein the  
diameter of the cylinder is between 4 and 10 mm.
5. An inhaler as claimed in any preceding claim,  
wherein the chamber is comparable in volume to the  
cyclone.
- 25 6. An inhaler as claimed in any of claims 1 to 4,  
wherein the chamber has a volume of around 300 ml.
7. An inhaler comprising:  
a chamber having a mouthpiece; and  
30 an aerosolising device having an inlet for taking  
in an airflow and an outlet for expelling an aerosol  
into the chamber,  
wherein the inlet of the aerosolising device is  
connected to the chamber, such that, in use, the airflow  
35 is drawn from the chamber to generate the aerosol.
8. An inhaler as claimed in claim 7, wherein the

- 12 -

chamber receives a plunger which is arranged to force air through the aerosolising device as the plunger moves through the chamber.

5     9.    An inhaler as claimed in claim 8, wherein the aerosolising device is mounted on the plunger.

10     10.   An inhaler comprising a chamber having a mouthpiece and a plunger received in the chamber, wherein the plunger is arranged to force air through an aerosolising device to generate an aerosol of medicament in the chamber for inhalation through the mouthpiece.

15

1 / 3




FIG. 1




FIG. 2

2 / 3




FIG. 3




FIG. 4



3 / 3




FIG. 5




FIG. 6

# INTERNATIONAL SEARCH REPORT

International Application No

PC1/EP 00/05831

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61M15/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61M

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 3 809 084 A (HANSEN L) 7 May 1974 (1974-05-07) column 5, line 25 - line 50; claim 1; figures ---	1
X	WO 92 04066 A (BISGAARD HANS) 19 March 1992 (1992-03-19) page 2, line 25 - line 30; claims 1,2; figures 1,2 ---	1,2,10
X	US 4 907 583 A (WETTERLIN KJELL I L ET AL) 13 March 1990 (1990-03-13) column 3, line 12 - line 46; figures 1,2 ---	1,2
X	US 5 579 760 A (KOHLE DIETER) 3 December 1996 (1996-12-03) column 7, line 28 -column 10, line 47; figures 2-4C ---	7-9
	--- -/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

11 October 2000

Date of mailing of the international search report

19/10/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Villeneuve, J-M

# INTERNATIONAL SEARCH REPORT

International Application No

PCI/EP 00/05831

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5 476 093 A (LANKINEN TAPIO) 19 December 1995 (1995-12-19) column 6, line 41 -column 8, line 2; figures ---	1-4
A	DE 27 22 701 A (SCHERING AG) 23 November 1978 (1978-11-23) claims; figure 1 ---	1
A	US 3 980 074 A (WATT PETER RIDGWAY ET AL) 14 September 1976 (1976-09-14) ---	
A	WO 94 05360 A (NORTON HEALTHCARE LTD ;ANGEL CLIVE GRAHAM (GB); HARRIS MARK ALEXAN) 17 March 1994 (1994-03-17) -----	

## INTERNATIONAL SEARCH REPORT

International Application No.

PCT/EP 00/05831

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 3809084 A	07-05-1974	AT 330951 B	26-07-1976
		AT 128471 A	15-10-1975
		BE 762948 A	16-08-1971
		CA 982005 A	20-01-1976
		CH 536119 A	30-04-1973
		DE 2106794 A	26-08-1971
		DK 132012 B	13-10-1975
		ES 194458 Y	01-04-1975
		FR 2078678 A	05-11-1971
		GB 1305172 A	31-01-1973
		HK 13176 A	19-03-1976
		JP 56001102 B	12-01-1981
		MY 7776 A	31-12-1976
		NL 7101065 A,B,	18-08-1971
		SE 381180 B	01-12-1975
		US 3653380 A	04-04-1972
		ZA 7100007 A	27-10-1971
WO 9204066 A	19-03-1992	DK 29791 A	21-08-1992
		AT 140629 T	15-08-1996
		AU 657492 B	16-03-1995
		AU 8507991 A	30-03-1992
		CA 2092614 A,C	13-03-1992
		DE 69121105 D	29-08-1996
		DE 69121105 T	12-12-1996
		EP 0548152 A	30-06-1993
		ES 2089228 T	01-10-1996
		FI 931016 A	08-03-1993
		GR 3021099 T	31-12-1996
		JP 6500717 T	27-01-1994
		LV 10059 A,B	10-05-1994
		NO 304817 B	22-02-1999
		RU 2095092 C	10-11-1997
US 4907583 A	13-03-1990	US 5755221 A	26-05-1998
		LT 584 A,B	27-12-1994
		SE 453566 B	15-02-1988
		SG 92094 G	17-03-1995
		AT 70720 T	15-01-1992
		AU 601400 B	13-09-1990
		AU 6960487 A	10-09-1987
		CA 1276848 A	27-11-1990
		CY 1798 A	17-02-1995
		DE 3775433 A	06-02-1992
		DE 3775433 D	06-02-1992
		DE 237507 T	19-05-1988
		DK 115487 A,B,	08-09-1987
		EG 18100 A	30-06-1993
		EP 0237507 A	16-09-1987
		ES 2000997 T	16-06-1992
		FI 871000 A,B,	08-09-1987
		GR 88300028 T	18-10-1988
		GR 3003451 T	17-02-1993
		HK 80194 A	19-08-1994
		HR 920761 A	30-04-1995
		HU 50639 A,B	28-03-1990
		IE 60112 B	01-06-1994
		IL 81686 A	06-09-1992

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 00/05831

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4907583 A		IN 168166 A	16-02-1991
		JP 2113284 C	21-11-1996
		JP 8024715 B	13-03-1996
		JP 62221366 A	29-09-1987
		KR 9607754 B	12-06-1996
		NO 870938 A,B,	08-09-1987
		NZ 219445 A	26-04-1990
		PH 25194 A	27-03-1991
		PT 84421 A,B	01-04-1987
		SE 8601060 A	08-09-1987
		SI 8710341 A,B	28-02-1997
		YU 34187 A	30-04-1989
		ZA 8701346 A	07-09-1987
US 5579760 A	03-12-1996	DE 4237568 C	11-05-1994
		AT 147277 T	15-01-1997
		AU 5570094 A	08-06-1994
		DE 59305095 D	20-02-1997
		WO 9411043 A	26-05-1994
		EP 0667793 A	23-08-1995
		JP 8506024 T	02-07-1996
		WO 9512428 A	11-05-1995
US 5476093 A	19-12-1995	NONE	
DE 2722701 A	23-11-1978	NONE	
US 3980074 A	14-09-1976	GB 1478138 A	29-06-1977
		AT 341110 B	25-01-1978
		AT 592774 A	15-05-1977
		AU 7140874 A	22-01-1976
		BE 817747 A	17-01-1975
		BR 7405926 A	09-03-1976
		CA 1027447 A	07-03-1978
		CH 573754 A	31-03-1976
		DE 2434421 A	06-02-1975
		DK 385374 A	03-03-1975
		ES 428388 A	16-07-1976
		FR 2237646 A	14-02-1975
		IE 39903 B	31-01-1979
		IL 45267 A	31-01-1977
		IT 1016439 B	30-05-1977
		JP 50029285 A	25-03-1975
		NL 7409646 A	21-01-1975
		PH 14276 A	29-04-1981
		SE 412006 B	18-02-1980
		SE 7409264 A	20-01-1975
		ZA 7404441 A	24-09-1975
WO 9405360 A	17-03-1994	AU 4976293 A	29-03-1994
		AU 4976393 A	29-03-1994
		CN 1084081 A	23-03-1994
		CN 1084082 A	23-03-1994
		WO 9405359 A	17-03-1994
		MX 9305472 A	29-04-1994
		MX 9305473 A	29-04-1994
		TR 27244 A	21-12-1994
		ZA 9306620 A	29-03-1994

## PC1/EP 00/05831

Form PCT/ISA/210 (patent family annex) (July 1992)